Published in The BMJ · View the paper (DOI)
A new study finds that rosiglitazone increases the risk of heart failure and cardiovascular events by 33% compared to controls. The research highlights the importance of access to raw clinical trial data for accurate drug safety assessments.
Coverage from 2 institutions